Product Manager

Latent raises $80M to close the gap between diagnosis and treatment. * Business Wire * 2 hrs ago SAN FRANCISCO-(BUSINESS WIRE)-Apr 7, 2026- Latent, the clinical-AI company accelerating access to life-saving medications, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems. Sri Somasundaram (left), Rish Jain (right), Co-CEOs and Co-Founders of Latent Modern medicine has advanced faster than the systems that deliver it. Today in the U.S., a patient and their doctor will sit together, look at a diagnosis, and decide on a treatment. In 42% of critical cases, that life-saving medication will be delayed or denied and may not reach the patient. This is not because the medicine doesn't exist or the doctor made the wrong call, but because every therapy a patient receives must pass through a gauntlet of clinical documentation, payer rules, and pharmacy coordination. Discover more Coupon publications Local sports coverage That gauntlet is currently held together by manual labor: clinicians toggling between systems, pharmacy teams re-keying information, staff navigating phone trees to prove what a patient's own chart already shows. The work is clinical in nature; it involves interpreting labs, applying treatment criteria, matching diagnoses to coverage rules. It is among the highest-stakes knowledge work in healthcare, and it is done almost entirely by hand. For the first time, AI makes it possible to close the distance between a therapeutic decision and a patient receiving therapy. Latent is building the Clinical Reasoning Engine. The engine performs clinical knowledge work by reasoning through patient data, interpreting drug criteria, extracting key evidence, and orchestrating workflows across stakeholders. By connecting the EHR, payer guidelines, pharmacy operations, and patient engagement with a single engine, Latent replaces the fragmented, manual work that sits between a doctor's order and a patient's treatment with AI agents that perform it instantly and at scale, all to help providers move a patient from decision to therapy the same day. Latent started with prior authorization, the most acute expression of the problem: high provider burnout, high stakes where patients can abandon therapy, and complex clinical decision-making. Meeting that challenge required mastering drug criteria and reasoning over medical records. Having demonstrated its ability to deliver on one of healthcare's hardest problems, the company is now expanding its engine across every process where clinical knowledge must be translated into action. Today, over2 million patientsannually are accessing life-changing medications faster because of Latent. Over the past year, the company has scaled from 4 to more than 45 health system partners and now serves 50% of the top 20 U.S. health systems - including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Across nearly every specialty and therapeutic area, Latent is reducing denials by more than 30% and enabling clinicians to serve twice as many patients. Discover more Senior lifestyle products Crosswords and contests Crossword puzzle books Looking to the future, Latent's Clinical Reasoning Engine will be applied proactively to identify when patients should begin therapy and ensure they stay on it. Every day, treatments that could help patients are delayed, denied or not identified. The company is building the infrastructure for the intersection of clinicians, patients, and payers, powering the knowledge work that determines what care patients actually receive. With the Series A financing, the company will expand its health system footprint, deepen the platform connecting hospitals, payers, pharmacies, and patients, continue investing in the reliability and trust required to operate in healthcare, and scale the team. Latent is a home for exceptional talent who believe responsibility doesn't end at diagnosis, it extends to making sure patients actually receive care. About Latent Health Latent Health is the leading AI platform for medication access. The company brings clinical intelligence directly into the patient record, helping care teams move patients from clinical decision to therapy faster and more reliably. Latent is helping more than 2 million patients annually and is trusted by more than 45 of the nation's leading health systems, including Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health, and UCLA Health. Founded by Sriram Somasundaram and Rishabh Jain, Latent has raised $80M in total funding from Transformation Capital, Spark Capital, McKesson Ventures, Conviction, General Catalyst, Y Combinator, and others. To learn more, visit latenthealth.com, and see open roles at latenthealth.com/careers. KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: SOFTWARE PHARMACEUTICAL HEALTH ARTIFICIAL INTELLIGENCE DATA MANAGEMENT HOSPITALS HEALTH TECHNOLOGY TECHNOLOGY PUB: 04/07/2026 04:23 PM/DISC: 04/07/2026 04:23 PM From the Web Powered by

Latent, the clinical-AI company accelerating access to life-saving medications, has raised an $80M Series A co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Today, Latent works with 50% of the top 20 U.S. health systems.